Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC002 in Advanced Solid Tumors
NCT07726212Phase 1Not yet recruiting
- Sponsor
- Hangzhou MacroLink Biopharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label, single-arm trial of MC-002 in esophageal cancer, lung cancer and solid tumor, sponsored by Hangzhou MacroLink Biopharmaceutical. Primary endpoints: Adverse Events and Maximum Tolerated Dose or Recommended Phase 2 Dose. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
MC-002
03
Conditions
esophageal cancerlung cancersolid tumor
Beyond the preview
Go deeper on NCT07726212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726212.